Jacobs Levy Equity Management, Inc Mirum Pharmaceuticals, Inc. Transaction History

Jacobs Levy Equity Management, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$17.59 - $23.83 $358,783 - $486,060	-20,397 Reduced 10.43%	175,122 $3.41 Million
Q3 2022 Nov 15, 2022	BUY	$19.98 - $29.44 $3.5 Million - $5.16 Million	175,282 Added 866.15%	195,519 $4.11 Million
Q2 2022 Aug 15, 2022	SELL	$18.42 - $27.5 $343,422 - $512,710	-18,644 Reduced 47.95%	20,237 $394,000
Q1 2022 May 16, 2022	SELL	$15.5 - $23.93 $4.09 Million - $6.31 Million	-263,677 Reduced 87.15%	38,881 $856,000
Q4 2021 Feb 14, 2022	BUY	$13.05 - $19.35 $1.8 Million - $2.67 Million	138,156 Added 84.04%	302,558 $4.83 Million
Q3 2021 Nov 15, 2021	BUY	$13.95 - $20.18 $1.28 Million - $1.85 Million	91,669 Added 126.03%	164,402 $3.28 Million
Q2 2021 Aug 16, 2021	BUY	$15.84 - $20.6 $782,400 - $1.02 Million	49,394 Added 211.64%	72,733 $1.26 Million
Q1 2021 May 17, 2021	BUY	$16.29 - $21.92 $380,192 - $511,590	23,339 New	23,339 $463,000

190

54M

177K

167K

Ticker MIRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,751,700
Market Cap $1.64B
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.